XGN (XGN) AI Stock Summary

Snapshot

Exagen is a small-cap diagnostics company that is growing its top line but burning cash to do so. FY 2025 revenue reached $66.6M, up 19.7% from the prior year, with a healthy 58.3% gross margin. However, the company lost $20.0M in net income, driven largely by $46.6M in sales and general administrative expenses (70% of revenue). The business generated negative free cash flow of $14.3M last year. It holds $32.2M in cash against $5.4M in debt, providing a comfortable runway of roughly 16 months at current burn rates. The share count increased by 18.4% over the last fiscal year, a significant dilutive signal for existing holders. The stock trades near its 52-week low, down 65.7% from its peak, reflecting investor caution about the path to profitability.

What's Happening Right Now

• Mon 1st Jun '26 · Clinical Validation: A new systematic review published in Lupus Science & Medicine confirms the superior diagnostic accuracy of Exagen's AVISE Lupus algorithm.
• Tue 12th May '26 · Dilution Risk: The company filed to register over 1.1 million new shares for employee compensation plans, signaling potential future dilution.
• Mon 11th May '26 · Earnings Beat: Exagen reported record Q1 2026 revenue of $17.3M, beating estimates, driven by higher test volume and improved pricing.

Ownership

Institutions hold 46.6% of the outstanding shares, while insiders hold 5.2%.

Bottom Line

Exagen is a classic growth-stage biotech story: the product works, revenue is accelerating, and the market for autoimmune testing is expanding. The concern is the cost of growth. With sales expenses consuming 70% of revenue, the company is spending heavily to acquire customers. The 16-month cash runway provides a buffer, but the recent 18% increase in share count shows that dilution is already part of the equation. The stock is cheap relative to its highs, but it is not profitable. A reader needs to believe that sales efficiency will improve significantly before the cash runs out to find a compelling case here.